Sophie Whyte - Publications

Journal articles

Conference proceedings papers

  • Faria R, Walker S, Whyte S, Dixon S, Sculpher M & Palmer S (2015) The value of implementation: how to invest in getting cost-effective technologies into practice. Framework and application to novel oral anticoagulants in the prevention of stroke and systemic embolism. HESG. Leeds
  • Faria R, Whyte S, Palmer S & Hoomans T (2014) WORKSHOP 2999: From evaluation to implementation: how to ensure efficient investment in implementation of cost-effective technologies in clinical practice?. ISPOR. Amsterdam, 9 November 2014 - 12 November 2014.
  • Whyte S, Dixon S, Faria R, Walker S, Sculpher M & Palmer S (2014) The value of investing in implementation activities: A case study in natriuretic peptide testing for diagnosing suspected heart failure. SMDM. Antwerp, Belgium
  • Rowen D, Brazier J, Mukuria C, Whyte S, Keetharuth A, Risa Hole A, Tsuchiya A & Shackley P (2014) Rowen D, Brazier J, Mukuria C, Whyte S, Keetharuth A, Risa Hole A, Tsuchiya A, Shackley P. Eliciting societal preferences for burden of illness, therapeutic improvement and end of life for value based pricing.. HESG. Sheffield, UK, 8 January 2014.
  • Asaria M, Griffin S, Cookson R, Whyte S & Tappenden P (2013) A framework for the cost-equality analysis of health care programmes. ISPOR. Dublin
  • Bessey A, Whyte S, Minton J & Chilcott J (2013) Economic evaluation of an electrical impedance spectroscopy (EIS) device used as an adjunct to colposcopy. VALUE IN HEALTH, Vol. 16(7) (pp A407-A407)
  • Whyte S (2013) Cost effectiveness analysis of an early awareness campaign for colorectal cancer. Cancer Outcomes Conference. Brighton
  • Whyte S (2013) Effectiveness and cost effectiveness of an awareness campaign for colorectal cancer: A mathematical modelling study. Cancer Research UK NAEDI conference. Cambridge, UK
  • Whyte S, Scope A & Tappenden P (2012) The cost effectiveness of an early awareness campaign for colorectal cancer. SMDM. Oslo, Norway
  • Whyte S & Chilcott J (2010) Using a natural history model in combination with screening data to estimate the test characteristics of the FOB test in the English bowel cancer screening programme. Methods for evaluating medical tests and biomarkers. Birmingham, UK
  • Whyte S (2009) Bayesian calibration of a natural history model for colorectal cancer. ISPOR. Paris
  • Kearns B, Chilcott & whyte () Flexible parametric survival models and time-series analysis for extrapolating time-varying treatment effects in health technology assessment. Flexible parametric survival models and time-series analysis for extrapolating time-varying treatment effects in health technology assessment, 5 September 2016 - 8 September 2016.

Reports

  • Pollard D, Cree I & Whyte S (2016) Generic Cancer Screen - Economic modelling report View this article in WRRO
  • Whyte S, Chambers D & Wong R (2015) Degarelix for treating advanced hormone-dependent Prostate cancer [ID590] Spinal cord compression associated with hormonal therapy in men with hormone-dependent metastatic prostate cancer: a systematic review and economic assessment
  • Faria R, Walker S, Whyte S, Dixon S, Palmer S & Sculpher M (2014) Getting cost-effective technologies into practice: the value of implementation An application to novel anticoagulants in the prevention of stroke and systemic embolism
  • Whyte S, Dixon S, Faria R, Walker S, Palmer S & Sculpher M (2014) Getting cost-effective technologies into practice: the value of implementation. An application to B-type natriuretic peptide (BNP) testing in diagnosing chronic heart failure View this article in WRRO
  • Walker S, Faria R, Whyte S, Dixon S, Palmer S & Sculpher M (2014) Getting cost-effective technologies into practice: the value of implementation. Report on framework for valuing implementation initiatives
  • Rowen D, Brazier J, Mukuria C, Keetharuth A, Rise Hole A, Tsuchiya A, Whyte S & Shackley P (2014) Update: Eliciting societal preferences for weighting QALY's according to burden of illness, size of gain and end of life View this article in WRRO
  • Whyte S, Brazier J, Rowen D, Mukuria C, Keetharuth A, RiseHole A, Tsuchiya A & Shackley P (2013) Eliciting societal preferences for burden of illness, therapeutic improvement and end of life for value based pricing: a report of the main survey View this article in WRRO
  • Whyte S, Harnan S, Scope A, Simpson E, Tappenden P, Duffy S, Rachet B, Sculpher M, Hinde S, McKenna C & Wong R (2012) Early awareness interventions for cancer: Colorectal cancer View this article in WRRO
  • Hinde S, McKenna C, Whyte S, Peake M, Callister M, Rogers T & Sculpher M (2012) Modelling the cost-effectiveness of early awareness interventions for the early detection of lung cancer
  • Whyte S, Cooper KL, Stevenson MD, Madan J & Akehurst R (2011) Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom
  • Whyte S, Cooper KL, Stevenson MD & Akehurst R (2011) Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in patients with non-Hodgkin's lymphoma in the United Kingdom (UK)
  • Whyte S, Chilcott J, Essat M, Stevens J, Wong R & Kalita N (2011) Reappraisal of the options for colorectal cancer screening View this article in WRRO
  • Madan J, Cooper KL, Stevenson MD, Whyte S & Akehurst R (2009) Consistency between direct trial evidence and Bayesian Mixed Treatment Comparison: Is head-to-head evidence always more reliable?
  • Cooper KL, Madan J, Whyte S, Stevenson MD & Akehurst R (2009) Granulocyte colony-stimulating factors for prevention of febrile neutropenia following chemotherapy: systematic review and meta-analysis
  • Sharp L, Whyte S, Ceillachair A, Comber H, Tilson L, Usher C, Walsh C, Barry M, Tappenden P, Chilcott J & Staines A (2009) Options for a population-based colorectal cancer screening programme in Ireland: a health technology assessment
  • Whyte S, Chilcott J & Headley J (2008) Health economics of Colonix: A new diagnostic test in colorectal cancer